The United States just received the first two treatments for idiopathic pulmonary fibrosis, however, while Boehringer Ingelheim GmbH‘s therapy, OFEV (nintedanib), will cost $96,000 per year, its competitor, Esbriet (pirfenidone) from InterMune/Roche Holding AG won’t cost much less, according to a news report from…
A research article published this month in the journal BMC Genomics finds that peripheral blood biomarkers might improve accuracy in diagnosing idiopathic pulmonary fibrosis (IPF) — which the National Heart, Lung, and Blood Institute describes as a disease in which tissue deep in the lungs…
ProMetic Life Sciences has just announced that it will begin research on the application of their lead pipeline product for pulmonary fibrosis, PBI-4050, in idiopathic pulmonary fibrosis (IPF), an unusual type of PF that leads to spontaneous lung scarring and is estimated to affect over 130,000 Americans. Every…
The U.S. Food and Drug Administration (FDA) recently approved two drugs that are the first therapies specifically directed for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States, Esbriet (pirfenidone), from InterMune, Inc., and OFEV (nintedanib), from…
An influx of research at the University of Colorado, Denver (UCD) concerning the use of Parion Science’s mucolytic agents to treat idiopathic pulmonary fibrosis (IPF), will be made possible by a $7.9 million-total grant from the National Institutes of Health (NIH). According to a press release from…
Idiopathic pulmonary fibrosis (IPF) patients received two pieces of good news just recently when the US Food and Drug Administration announced that it has granted approval for two IPF treatments: Esbriet® (pirfenidone) from InterMune, Inc., and Ofev…
Earlier this month, a second province in Canada finally approved novel pulmonary fibrosis drug Esbriet (pirfenidone) for public funding, which is a giant leap towards improving the lives of thousands of individuals living with idiopathic pulmonary fibrosis…
New Brunswick, Canada residents currently in the fight against a rare and mysterious disease, idiopathic pulmonary fibrosis (IPF), have received new hope after it was announced that the provincial government has added Esbriet (pirfenidone) to the list of treatments publicly funded under the New Brunswick Prescription Drug…
Asbestos exposure has traditionally been linked to Mesothelioma. Now, however, IPF is also being associated with exposure to asbestos in some cases as well. Mesothelioma, a rare type of cancer that affects the protective lining of internal organs, is a common consequence of asbestos exposure. It can…
Seo Hyo-seok, a specialist in Korean traditional medicine, is visiting the United States for a week to promote his unique technique for the treatment of chronic lung conditions like asthma, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). The doctor is the head of the Pyunkang Korean…
Get regular updates to your inbox.
